These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2004-003999-11 GEMZAR AS PROLONGED INFUSION IN COMBINATION WITH PACLITAXEL IN ANTHRACYCLINE PRETREATED METASATTIC BREAST CANCER bad-data
Completed, but no date 2004-004146-40 pILOT STUDY TO EVALUATE QUALITY OF LIFE, SEIZURES CONTROL AND SIDE EFFECTS IN PATIENTS WITH BRAIN TUMORS AND EPILEPSY TREATED WITH LEVETIRACETAM IN MONOTHERAPY bad-data
Completed, but no date Terminated 2004-004288-31 Phase II parallel studies on the use of 3D-radiotherapy plus Amifostine or IMRT to evaluate xerostomia reduction in patients with head and neck cancer treated in definitve or postoperative setting. bad-data
Completed, but no date Terminated 2005-000452-32 DOCETAXEL AND GEMCITABINE IN THE TREATMENT OF UNKNOWN PRIMARY TUMORS - A PHASE II STUDY - bad-data
Ongoing 2005-005063-29 Induction Chemotherapy with Gemcitabine-Oxaliplatin GEM-OXA followed by concomitant weekly Gemcitabine plus Radiotherapy GEM/RT in Locally Advanced, Unresectable Pancreatic Cancer A Phase II Stu... not-yet-due
Completed, but no date 2005-006205-28 Role of Erbitux plus a combination of CPT-11/5-fluorouracil/leucovorin/oxaliplatin as neoadjuvant chemotherapy in patients with colorectal liver metastases bad-data
Completed, but no date Terminated 2006-000285-36 Protocol for a pilot study examining the impact of Metformin use on serum testosterone levels in postmenopausal women bad-data
Completed, but no date Terminated 2006-001425-25 Neoadjuvant treatment in high risk superficial soft tissue sarcomas of limbs and soft tissue of the trunk phase II study bad-data
Completed, but no date 2006-001545-34 Evaluating primary chemotherapy with temozolomide continuative low dose in patients with low grade gliomas grade II WHO bad-data
Completed, but no date Terminated 2006-002708-33 RANDOMIZED PHASE III TRIAL OF PREOPERATIVE VERSUS POSTOPERATIVE CHEMOTHERAPY WITH CISPLATIN AND GEMCITABINE IN STAGE IB-IIIA NON-SMALL CELL LUNG CANCER NSCLC bad-data
Completed, but no date 2006-002742-11 MULTICENTER PHASE II TRIAL OF TARCEVA COMBINED WITH FIXED DOSE-RATE GEMCITABINE INFUSION AS FIRST LINE TREATMENT OF ADVANCED, UNRESECTABLE PANCREATIC CANCER bad-data
Completed, but no date 2006-004791-12 VALUTATION OF AN ORAL HYPOSENSITIZATION TREATMENT IN PATIENTS WITH ALLERGIC CONTACT DERMATITIS TO NICKEL SULPHATE bad-data
Ongoing 2007-003466-18 PHASE II TRIAL OF PRIMARY CHEMOTHERAPY WITH TRASTUZUMAB IN COMBINATION WITH DOCETAXEL FOLLOWED BY EPIRUBICIN-CYCLOPHOSPHAMIDE IN PATIENTS WITH HER2-OVEREXPRESSING OPERABLE BREAST CANCER not-yet-due
Completed, but no date 2008-003342-29 Second line therapy with low dose fotemustine in progressive malignant gliomas bad-data
Completed, but no date Terminated 2008-003525-16 Neoadjuvant chemotherapy with weekly docetaxel followed from concomitant docetaxel-RT in patients with high risk locally advanced prostate cancer bad-data
Completed, but no date Terminated 2008-004988-19 A PHASE II STUDY, COMPARING A DOSE-TITRATION REGIMEN OF FULVESTRANT WITH THE APPROVED DOSING REGIMEN IN POSTMENOPAUSAL PATIENTS WITH HORMONE-RESPONSIVE ADVANCED BREAST CANCER (ABC) bad-data
Not reported Terminated 2008-006899-30 PHASE II STUDY OF 90Y-IBRITUMOMAB TIUXETAN AND FOTEMUSTINE ASSOCIATED WITH CYTARABINE ETOPOSIDE MELPHALAN AS CONDITIONING CHEMORADIOIMMUNOTHERAPY IN PATIENTS AFFECTED BY LYMPHOMA (HODGKIN AND NON-HODG... 2011-03-04 due-trials
Ongoing 2009-009921-28 The Effect of Metformin, an insulin-sensitizing drug, on Breast Cancer Primary Prevention: The Plotina Breast Cancer Prevention Randomized, Placebo Controlled Trial not-yet-due
Ongoing 2009-011189-27 Phase III prospective clinical trial: 18F-FCH/PET evaluation in early diagnosis of disease recurrence in prostate cancer not-yet-due
Ongoing 2010-019740-39 Isotonic contrast (iodixanol) administration vs. low osmolar contrast (iopromide) use: evaluating risk of contrast-induced nephropathy in cancer patients at very low risk not-yet-due
Ongoing 2012-000834-21 Molecular Biomarkers for Colorectal Liver Metastases Resectability after Chemotherapy with Cetuximab MARCATORI BIOMOLECOLARI DI RESECABILITA' PER METASTASI EPATICHE COLORETTALI TRATTATE CON CHEMIOT... not-yet-due
Ongoing 2013-001834-16 EVALUATION OF SEIZURE CONTROL AND QUALITY OF LIFE IN PATIENTS WITH BRAIN TUMOR RELATED EPILEPSY TREATED WITH LACOSAMIDE AS ADD-ON THERAPY: A PROSPECTIVE EXPLORATIVE STUDY VALUTAZIONE DEL CONTROLLO ... not-yet-due
Ongoing 2013-004562-33 PHASE II STUDY TO EVALUATE SAFETY AND EFFICACY OF A BIO-RIASSORBABLE SUBCUTANEOUS IMPLANT OF AFAMELANOTIDE IN HAILEY-HAILEY DISEASE (HHD) PATIENTS Studio, di fase II, per valutare la sicurezza e l’... not-yet-due
Exempt 2013-005134-38 Phase I-II study of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) in combination with liposomal encapsulated doxorubicin (LDox) in patients with HER2 negative metastatic breast c... not-yet-due
Ongoing 2014-005508-62 A phase II, randomized, non-comparative, pre-surgical study of atorvastatin or observation in Ki-67 positive, TAZ-expressing early breast cancer patients Atorvastatina vs osservazione in pazienti ... not-yet-due
Ongoing 2015-002751-10 DIFFERENCE BETWEEN NEUROCOGNITIVE IMPACT WITH CHEMOTHERAPY AND RADIATION THERAPY HYPOFRACTIONATED TEMOZOLOMIDE AS SINGLE AGENT IN ELDERLY PATIENTS (= 70 YEARS) WITH NEWLY DIAGNOSED GLIOBLASTOMA: A MUL... not-yet-due
Completed, but no date 2017-001695-26 Monitoring the effectiveness and safety of biological drugs for treatment of psoriasis through evaluation of clinical and biological markers Monitoraggio dell'efficacia e sicurezza di farmaci biolo... bad-data
Completed, but no date Terminated 2019-001641-40 Induction Durvalumab (MEDI4736) & Radiotherapy (RT) for Locally Advanced but Resectable Head and Neck Squamous Cell Carcinomas: A Pilot Study Studio pilota di induzione con Durvalumab (MEDI4736) e ... bad-data
Ongoing 2019-001988-75 REPURPOSING THE ANTIPSYCHOTIC DRUG CLORPROMAZINE AS A THERAPEUTIC AGENT IN THE COMBINED TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME Riposizionamento dell’antipsicotico clorpromazina come a... not-yet-due
Ongoing 2019-002181-12 EXPLORING OPTIMAL SEQUENCE TREATMENT IN HER2+ PERTUZUMAB PRE- TREATED ADVANCED BREAST CANCER PATIENTS. THE STEP TRIAL. VALUTAZIONE DELLA SEQUENZA OTTIMALE DI TRATTAMENTO NELLE PAZIENTI AFFETTE DA C... not-yet-due
Ongoing 2020-004195-17 Sbrt±sTad for Unfavorable iNtermediate rIsk/high risk prostate caNcer (STUNNIN): A Randomized Phase II Study Sbrt±sTad per il tumore prostatico a rischio intermedio sfavorevole/alto rischio (STUNNI... not-yet-due
Ongoing 2021-001442-35 A PHASE 2 MONOCENTRIC PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PIOGLITAZONE IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO STUDIO PILOTA DI FASE 2 PER LA VALUTAZIONE DELL’EFFICACI... not-yet-due
Ongoing 2021-002632-23 A proof-of-concept, biomarker-driven, phase-II clinical trial to explore the activity of decitabine repurposing against advanced, refractory, KRAS-dependent pancreatic ductal adenocarcinoma (PDAC): T... not-yet-due